<DOC>
	<DOCNO>NCT01551524</DOCNO>
	<brief_summary>This study open label , multicenter study dose escalation AsparecÂ® administer every two four week two administration . The primary objective study determine Maximum Tolerated Dose follow one single dose Asparec administer population patient relapse refractory hematological malignancy , measure Dose Limiting toxicity . There secondary objective evaluate safety Asparec determine PK profile assess measurement plasma L-asparaginase enzymatic activity follow single repeat dos Asparec . Patients response rate evaluate Anti-Asparec antibody measure .</brief_summary>
	<brief_title>Phase I Study mPEG-R-Crisantaspase Given IV</brief_title>
	<detailed_description>Planned sample size : Up 36 evaluable subject enrol study : maximum 30 subject dose escalation phase maximum 12 patient expansion phase . Inclusion criterion consist : Patients relapse refractory hematological malignancy , standard curative life prolong treatment exist , longer effective tolerable . For follow hematological malignancy , patient must receive least : Low rade NHL : 3 prior line therapy , ALL , aggressive NHL hematological malignancy : 2 prior line therapy , Aged 18 50 year ECOG performance status 1 , 1 2 . All patient treat Asparec every two four week two IV administration infuse 60 minute . Patients without Disease Progression may receive additional administration , administration start least 14 day later 28 day previous Asparec administration .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Patients relapse refractory hematological malignancy , standard curative life prolong treatment exist , longer effective tolerable . For follow hematological malignancy , patient must receive least : Low grade NHL : 3 prior line therapy ALL , aggressive NHL hematological malignancy : 2 prior line therapy . Ages 18 50 year ECOG performance status 0 , 1 2 , ability understand sign write informed consent life expectancy great equal 90 day Any active CNS disease , previous great equal grade 3 allergic reaction Erwinase , patient experience great equal grade 3 allergic reaction E. coli Lasparaginase never receive E. chrysanthemi Lasparaginase occurrence reaction , WBC count great 20 Gica/L , follow laboratory abnormality due hematologic malignancy ( calculated creatinine clearance le 50 mL/min , serum SGOT/AST SGPT ? ALT great 2.5 x upper limit normal , serum total bilirubin great 2.0 mg/dL , except case hemolytic anemia . Patients history great equal grade 2 pancreatitis , history allogeneic transplant , receive steroid therapy dose great 20 mg/day , know HIV positive serology , active hepatitis B C , serious active disease comorbid medical condition psychiatric illness would prevent subject signing informed consent . Pregnant lactate female woman child bear potential willing use adequate method birth control duration study eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>C240588.448</keyword>
	<keyword>C115.378.400</keyword>
</DOC>